Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.
| Revenue (Most Recent Fiscal Year) | $87.68M |
| Net Income (Most Recent Fiscal Year) | $-29.67M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.55 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -26.49% |
| Net Margin (Trailing 12 Months) | -26.03% |
| Return on Equity (Trailing 12 Months) | -24.60% |
| Return on Assets (Trailing 12 Months) | -18.89% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.00 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.58 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.80 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.67 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.50 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.44M |
| Free Float | 36.49M |
| Market Capitalization | $388.50M |
| Average Volume (Last 20 Days) | 2.08M |
| Beta (Past 60 Months) | 0.57 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 19.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 70.85% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |